Clinical trials

VCN-01 (intratumoral) + Chemotherapy for patients with Advanced Pancreatic Cancer
STUDY FINALIZED
Study P-VCNA-002 is a phase I trial to evaluate the safety and efficacy of intratumoral injections of VCN-01 oncolytic adenovirus in combination with intravenous  Abraxane® and Gemcitabine in adult patients with histologically confirmed diagnosis of unresectable pancreatic adenocarcinoma amenable to Ultra Sound-guided injection.
P-VCNA-002 clinical trial page

 

VCN-01 (intravenous) + Chemotherapy for patients with Advanced Solid tumours
RECRUITMENT FINALIZED – IN FOLLOW-UP
Study P-VCNA-001 is a phase I trial to evaluate the safety and efficacy of intravenous injection of VCN-01 oncolytic adenovirus alone or in combination with Abraxane® and Gemcitabine in advanced cancer. The study consists in three parts: Part I is a dose scalation study of VCN-01 in monotherapy in patients with advanced solid tumors; Part II is a dose scalation study of VCN-01 in concomitant combination with Abraxane® and Gemcitabine in advanced pancreatic adenocarcinoma; Part III is a dose scalation study of VCN-01 in a 1-week delayed schedule in combination with Abraxane® and Gemcitabine in advanced pancreatic adenocarcinoma amenable for biopsy collection.
P-VCNA-001 clinical trial page

 dibu virus 01

 

INVESTIGATOR SPONSORED CLINICAL TRIALS

VCN-01 (intravenous) + PD-L1 checkpoint inhibitor for patients with R/M HNSCC
ACTIVE RECRUITMENT
Study ICO-VCN-H&N-2018 is a Phase I trial to Evaluate the Safety, Tolerability, and Efficacy of intravenous injection of VCN-01 oncolytic adenovirus in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
The study is a VCN-01 dose escalation trial combined with a fixed dose of durvalumab in concomitant or 2-weeks delayed schedule.
ICO-VCN-H&N-2018 clinical trial page
Sponsor: Institut Català d’Oncologia

 

VCN-01 (intravitreal) for patients with Refractory Retinoblastoma  
ACTIVE RECRUITMENT
Study FSJD-RTB-2015 is a Phase I trial to Evaluate the Safety and Activity of intravitreal injection of VCN-01 oncolytic adenovirus in Pediatric Population with Refractory Retinoblastoma
The study is a VCN-01 dose escalation trial that consist on two intravitreal injections administered at D1 and D15
FSJD-RTB-2015 clinical trial page
Sponsor: Fundació Sant Joan de Déu